Skip to main content

Table 1 Meta-analysis of Danhong injection with the changes in plasma lipid levels

From: The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials

Groups or subgroups

Studies (Subjects)

P Heterogeneity

SMD (95% CI)

P SMD

Triglycerides

 All

38 (4213)

<  0.001

− 0.76 (− 0.91, − 0.61)

<  0.001

 Coronary artery disease

7 (790)

<  0.001

− 0.52 (− 0.88, − 0.16)

<  0.01

 Cerebrovascular disease

16 (2218)

<  0.001

− 0.94 (− 1.13, − 0.74)

<  0.001

 Diabetes

9 (695)

0.001

− 0.58 (− 0.87, − 0.29)

<  0.001

 Hyperlipidemia

5 (444)

<  0.001

− 0.87 (− 1.54, − 0.20)

<  0.05

 Low-dose (≤ 20 mL)

13 (1257)

<  0.001

− 0.90 (− 1.15, − 0.66)

<  0.001

 High-dose (>  20 mL)

25 (2956)

<  0.001

− 0.69 (− 0.88, − 0.50)

<  0.001

 Short-duration (≤ 2 weeks)

20 (2472)

<  0.001

− 0.76 (− 0.99, − 0.53)

<  0.001

 Long-duration (>  2 weeks)

17 (1661)

<  0.001

− 0.80 (− 0.99, − 0.61)

<  0.001

Total cholesterol

 All

41 (4781)

<  0.001

− 1.29 (− 1.56, − 1.03)

<  0.001

 Coronary artery disease

7 (982)

<  0.001

− 1.12 (− 1.85, − 0.40)

<  0.01

 Cerebrovascular disease

18 (2390)

<  0.001

− 1.53 (− 1.94, − 1.13)

<  0.001

 Diabetes

9 (695)

<  0.001

− 1.28 (− 1.87, − 0.70)

<  0.001

 Hyperlipidemia

6 (648)

0.08

−1.16 (− 1.46, − 0.86)

<  0.001

 Low-dose (≤ 20 mL)

13 (1449)

<  0.001

− 1.13 (− 1.49, − 0.78)

<  0.001

 High-dose (>  20 mL)

28 (3332)

<  0.001

− 1.38 (− 1.73, − 1.02)

<  0.001

 Short-duration (≤ 2 weeks)

21 (2544)

<  0.001

− 1.12 (− 1.38, − 0.86)

<  0.001

 Long-duration (>  2 weeks)

19 (2157)

<  0.001

− 1.42 (− 1.92, − 0.92)

<  0.001

LDL-C

    

 All

38 (4412)

<  0.001

− 0.76 (− 0.93, − 0.59)

<  0.001

 Coronary artery disease

8 (1012)

<  0.001

− 0.72 (− 1.15, − 0.30)

0.001

 Cerebrovascular disease

16 (2183)

<  0.001

− 0.94 (− 1.24, − 0.64)

<  0.001

 Diabetes

7 (503)

0.02

− 0.56 (− 0.86, − 0.26)

<  0.001

 Hyperlipidemia

5 (444)

0.34

−0.54 (− 0.74, − 0.34)

<  0.001

 Low-dose (≤ 20 mL)

14 (1579)

<  0.001

− 0.79 (− 1.05, − 0.53)

<  0.001

 High-dose (>  20 mL)

24 (2833)

<  0.001

− 0.74 (− 0.96, − 0.52)

<  0.001

 Short-duration (≤ 2 weeks)

18 (2115)

<  0.001

− 0.71 (− 0.92, − 0.50)

<  0.001

 Long-duration (>  2 weeks)

19 (2217)

<  0.001

−0.85 (− 1.11, − 0.58)

<  0.001

HDL-C

 All

32 (3616)

<  0.001

0.70 (0.41, 0.98)

<  0.001

 Coronary artery disease

5 (500)

<  0.001

0.75 (−0.00, 1.50)

0.05

 Cerebrovascular disease

17 (2318)

<  0.001

0.98 (0.55, 1.41)

<  0.001

 Diabetes

4 (288)

0.10

0.32 (−0.07, 0.70)

0.10

 Hyperlipidemia

5 (444)

<  0.001

0.19 (−0.32, 0.69)

0.47

 Low-dose (≤ 20 mL)

11 (1032)

<  0.01

0.53 (0.33, 0.73)

<  0.001

 High-dose (>  20 mL)

21 (2584)

<  0.001

0.79 (0.38, 1.21)

<  0.001

 Short-duration (≤ 2 weeks)

16 (2070)

<  0.001

0.92 (0.55, 1.29)

<  0.001

 Long-duration (>  2 weeks)

15 (1466)

<  0.001

0.51 (0.07, 0.95)

0.02

  1. SMD standardized mean difference, 95% CI 95% confidence interval, TG triglycerides, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol